TOMI Environmental Solutions TOMZ

NASDAQ TOMZ

$1.63 -0.04 (-2.40%)

As of: Sep 10, 2026 · 3:56 PM EDT

Key Stats

Market Cap12.38 Mn

P/E-3.59

P/S1.79

Div. Yield0.00

Revenue Growth (1y) (Qtr)117.91

Add ratio to table…

About

TOMI Environmental Solutions, Inc. is a global provider of disinfection and decontamination solutions, offering environmentally friendly products and services for indoor air and surface treatment. The company’s flagship product line, SteraMist, uses patented Binary Ionization Technology (BIT) to deliver a low-concentration hydrogen peroxide-based fog or mist that treats indoor environments and achieves a 6-log kill rate against pathogens, leaving only oxygen and humidity…

TOMI generates revenue from equipment sales, BIT Solution consumables, corporate decontamination services, and Installation/Operational/Performance Qualification (IQ/OQ/PQ) services. The company operates on a razor-blade model where equipment sales drive recurring revenue from BIT Solution usage. Revenue is derived across its four divisions through direct sales, independent representatives, and a global network of distributors and certified service providers under the SteraMist Pro Certified program.

The company operates through the following segments: Life Sciences, Hospital-Healthcare, Food Safety, and Commercial.

Life Sciences: This segment targets pharmaceutical manufacturers, Contract Development and Manufacturing Organizations (CDMOs), and research institutions requiring automated, validated decontamination with minimal downtime. Product offerings include Custom Engineered System (CES), Hybrid, and SteraMist Integration System (SIS) lines, all undergoing full IQ/OQ/PQ validation. The onshoring of pharmaceutical manufacturing in Virginia with commitments from Merck, Eli Lilly, and AstraZeneca supports expanded adoption in this sector.
Hospital-Healthcare: This segment addresses healthcare-associated infections by providing rapid-turnaround disinfection for operating rooms, pharmacies, ambulances, and emergency environments. TOMI expands presence through partnerships with group purchasing organizations such as Vizient and educational campaigns for facility managers and infection control professionals. The segment leverages SteraMist’s efficiency in high-turnover clinical settings.
Food Safety: This segment benefits from the FDA’s 2025 final rule broadening hydrogen peroxide use as a direct food additive, enabling iHP application on food contact surfaces and ready-to-eat products. TOMI has conducted specialized tests with industry stakeholders on pathogens like Listeria monocytogenes using food items such as cheese, strawberries, and cut cantaloupe. The segment serves customers including Nestle, Sensient Technologies Corporation, and Danone.
Commercial: This segment serves aviation, hospitality, education, government, emergency services, and restoration sectors through certified service providers. Relationships include large franchise networks such as T. A. C. T. (18 U. S. locations) and Steri-Clean (approximately 60 franchises). SteraMist’s rapid deployment, no preconditioning needs, and minimal PPE requirements make it suitable for high-frequency commercial use in schools, transportation, and hospitality.

TOMI operates in a competitive disinfection and decontamination industry with players such as Steris Corporation, Bioquell (owned by Ecolab), and The Clorox Company, as well as ultraviolet and quaternary ammonium chemical companies. Its SteraMist iHP technology achieves a 6-log kill rate, surpassing most household and industrial disinfectants. Competitive advantages include its ready-to-use formula, ability to reach surfaces beyond traditional sprays, no rinse or wipe requirement, gentleness on electronics, minimal PPE needs, and DOT transport advantage due to its 7.8% hydrogen peroxide concentration falling below air shipment restrictions.

TOMI’s customers include Fortune 100 pharmaceutical and healthcare companies such as Pfizer, Merck, AbbVie, Bausch & Lomb, ThermoFisher Scientific, Eli Lilly and Company, FUJIFILM Diosynth Biotechnologies USA, and Fresenius Kabi. Government clients include the National Institutes of Health, U. S. Department of Agriculture, Centers for Disease Control and Prevention, United States Army Medical Research Institute of Infectious Diseases, and NASA’s Johnson Space Center. In food safety, customers encompass Nestle, Sensient Technologies Corporation, Mayorga Organics, Lakeview Farms LLC, Batory Foods, Danone, and Perdue. Healthcare customers also include Tower Health, Novant Health, Corewell Health, NorthEast Medical Services, St. Jude Children’s Research Hospital, Edgewell Personal Care, and Mass General Brigham.

Investment Thesis

▲ Bull case

The company reported a 16% increase in backlog for support services and a 24% increase in backlog for BIT solution in the Q1 FY26 compared to the same period last year indicating growing demand for recurring services. This trend suggests that customers are shifting from one time equipment purchases to ongoing service contracts which creates more predictable revenue streams. Management highlighted that the shift to open BIT solution orders and annual service offerings is driven by improved training programs and better ability to forecast solution consumption. The resulting increase in service revenue improves margins and reduces reliance on volatile capital expenditure cycles.
The OEM partnership strategy with PBSC ESCO and Steelco integrates the iHP technology directly into clean room enclosures pass through hatches and biosafety cabinets at the point of manufacture. This approach creates a scalable distribution channel that expands reach without proportionally increasing direct sales costs. Early collaboration with PBSC produced an iHP pass through that exceeded decontamination cycle speed expectations and generated strong customer feedback leading to a second project. By embedding the technology in partner equipment the company can leverage the partners sales force and installed base to drive adoption while keeping its own overhead low.
The FDA's late 2025 approval of hydrogen peroxide as a direct food additive for multiple uses including antimicrobial and bleaching creates a regulatory tailwind for the food safety segment. Management is actively pursuing a food contact notification for powdered infant formula in response to an existing customer request which could unlock a large niche market. In addition the company awaits EPA approval of a minus four label for cannabis and other requested markets which would allow broader use in agriculture and vertical farming. Successful navigation of these regulatory pathways would diversify revenue streams beyond the traditional life science and healthcare focus.
The company notes that obtaining FDA 510k clearance would enable it to pursue the entire ethylene oxide sterilization market which was valued at 5.29 billion dollars in the prior year. Success in this market would represent a substantial growth avenue given rising demand for sterilized medical consumables and improved healthcare infrastructure. Internationally the business has secured recognition in the United Kingdom the Netherlands and is progressing with additional EU registrations which should facilitate sales through existing distributors. The combination of a large addressable medical sterilization market and expanding international footprint provides a structural shift that could drive revenue well above current levels.

The company reported a 16% increase in backlog for support services and a 24% increase in backlog for BIT solution in the Q1 FY26 compared to the same period last year indicating growing demand for recurring services. This trend suggests that customers are shifting from one time equipment purchases to ongoing service contracts which creates more predictable revenue streams. Management highlighted that the shift to open BIT solution orders and annual service offerings is driven by improved training programs and better ability to forecast solution consumption. The resulting increase in service revenue improves margins and reduces reliance on volatile capital expenditure cycles.
The OEM partnership strategy with PBSC ESCO and Steelco integrates the iHP technology directly into clean room enclosures pass through hatches and biosafety cabinets at the point of manufacture. This approach creates a scalable distribution channel that expands reach without proportionally increasing direct sales costs. Early collaboration with PBSC produced an iHP pass through that exceeded decontamination cycle speed expectations and generated strong customer feedback leading to a second project. By embedding the technology in partner equipment the company can leverage the partners sales force and installed base to drive adoption while keeping its own overhead low.
The FDA's late 2025 approval of hydrogen peroxide as a direct food additive for multiple uses including antimicrobial and bleaching creates a regulatory tailwind for the food safety segment. Management is actively pursuing a food contact notification for powdered infant formula in response to an existing customer request which could unlock a large niche market. In addition the company awaits EPA approval of a minus four label for cannabis and other requested markets which would allow broader use in agriculture and vertical farming. Successful navigation of these regulatory pathways would diversify revenue streams beyond the traditional life science and healthcare focus.
The company notes that obtaining FDA 510k clearance would enable it to pursue the entire ethylene oxide sterilization market which was valued at 5.29 billion dollars in the prior year. Success in this market would represent a substantial growth avenue given rising demand for sterilized medical consumables and improved healthcare infrastructure. Internationally the business has secured recognition in the United Kingdom the Netherlands and is progressing with additional EU registrations which should facilitate sales through existing distributors. The combination of a large addressable medical sterilization market and expanding international footprint provides a structural shift that could drive revenue well above current levels.

▼ Bear case

The company ended 2025 with only approximately eighty eight thousand dollars in cash and used 1.2 million dollars in operating cash during the year indicating a tight liquidity position. Although it has secured a twenty million dollar equity line of credit with Hudson Global Ventures and drawn about ninety four thousand dollars the reliance on external financing raises the risk of shareholder dilution if additional draws are needed. Management also mentions a S3 shelf registration for up to fifty million dollars which could further increase dilution if utilized to fund operations. The need for continual capital inflows to support working capital and growth initiatives makes the balance sheet a vulnerability that the market may be underestimating.
Several customers have delayed capital expenditure projects citing DOGE tariffs and political uncertainty including the war which directly impacted 2025 revenue and could continue to affect order timing in 2026. The CEO noted that a major west coast university postponed a purchase until the end of 2026 due to those same factors showing that macro external pressures can override internal sales momentum. Because a significant portion of the pipeline depends on a limited number of large accounts any further deferrals could disproportionately impact revenue recognition. The business model therefore remains exposed to cyclical political and trade policy shifts that are difficult to predict or control.
While the company has highlighted pending FDA food contact notifications and EPA label approvals the timelines for these regulatory outcomes are uncertain and any delay would postpone expected revenue from new verticals such as infant formula and cannabis. The life science sterilization market is served by established technologies including ethylene oxide vaporized hydrogen peroxide and other low temperature sterilizers creating strong competition for the iHP platform. Success in securing FDA 510k clearance is not guaranteed and failure would limit the company ability to address the large ethylene oxide market. The reliance on regulatory approvals as a near term catalyst introduces execution risk that could cause the market to overestimate near term growth.
The company operates with a small team of approximately twenty employees which may constrain its ability to scale operations quickly if a large influx of orders materializes. Although OEM partnerships with PBSC ESCO and Steelco provide a distribution channel they also create dependence on partners sales efforts and integration timelines that are outside of the company direct control. Growth through partnerships can dilute margins if revenue sharing arrangements are required and may slow the pace of product adoption relative to a direct sales force. The combination of limited internal resources and reliance on external partners could hinder the company capacity to convert its pipeline into revenue at the speed implied by its optimistic outlook.

The company ended 2025 with only approximately eighty eight thousand dollars in cash and used 1.2 million dollars in operating cash during the year indicating a tight liquidity position. Although it has secured a twenty million dollar equity line of credit with Hudson Global Ventures and drawn about ninety four thousand dollars the reliance on external financing raises the risk of shareholder dilution if additional draws are needed. Management also mentions a S3 shelf registration for up to fifty million dollars which could further increase dilution if utilized to fund operations. The need for continual capital inflows to support working capital and growth initiatives makes the balance sheet a vulnerability that the market may be underestimating.
Several customers have delayed capital expenditure projects citing DOGE tariffs and political uncertainty including the war which directly impacted 2025 revenue and could continue to affect order timing in 2026. The CEO noted that a major west coast university postponed a purchase until the end of 2026 due to those same factors showing that macro external pressures can override internal sales momentum. Because a significant portion of the pipeline depends on a limited number of large accounts any further deferrals could disproportionately impact revenue recognition. The business model therefore remains exposed to cyclical political and trade policy shifts that are difficult to predict or control.
While the company has highlighted pending FDA food contact notifications and EPA label approvals the timelines for these regulatory outcomes are uncertain and any delay would postpone expected revenue from new verticals such as infant formula and cannabis. The life science sterilization market is served by established technologies including ethylene oxide vaporized hydrogen peroxide and other low temperature sterilizers creating strong competition for the iHP platform. Success in securing FDA 510k clearance is not guaranteed and failure would limit the company ability to address the large ethylene oxide market. The reliance on regulatory approvals as a near term catalyst introduces execution risk that could cause the market to overestimate near term growth.
The company operates with a small team of approximately twenty employees which may constrain its ability to scale operations quickly if a large influx of orders materializes. Although OEM partnerships with PBSC ESCO and Steelco provide a distribution channel they also create dependence on partners sales efforts and integration timelines that are outside of the company direct control. Growth through partnerships can dilute margins if revenue sharing arrangements are required and may slow the pace of product adoption relative to a direct sales force. The combination of limited internal resources and reliance on external partners could hinder the company capacity to convert its pipeline into revenue at the speed implied by its optimistic outlook.

Statement Geographical Axis Breakdown of Revenue (2022)

Peer group

Peer Comparison

Companies in the Pollution Control Equipment

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CECO	Ceco Environmental Corp	primary	3.26 Bn	-115.82	3.61	727.71 Mn
2	LNZA	LanzaTech Global, Inc.	primary	0.07 Bn	-1.20	1.24	12.70 Mn
3	FTEK	Fuel Tech, Inc.	primary	0.05 Bn	-14.65	1.87	-
4	SCWO	374Water Inc.	primary	0.04 Bn	-2.13	22.01	0.05 Mn
5	BCHT	Birchtech Corp.	primary	0.03 Bn	-7.44	1.35	-
6	CLIR	ClearSign Technologies Corp	primary	0.02 Bn	-3.83	4.24	-
7	LIQT	Liqtech International Inc	primary	0.01 Bn	-1.86	0.97	1.14 Mn
8	TOMZ	TOMI Environmental Solutions, Inc.	primary	0.01 Bn	-3.59	1.79	-

TOMI Environmental Solutions TOMZ

About

Investment Thesis

Statement Geographical Axis Breakdown of Revenue (2022)

Peer Comparison

Create an account

Sign In

Reset Password